Polymarket
New COVID variant of concern before 2027?
New COVID variant of concern before 2027?
18.5%Volume 243.09K
Repligen Corporation
RGEN · NASDAQ
Analyst ratings
strong_buy · 9 ratings
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| July 6, 2026 | Evercore ISI Group | Maintains | Outperform | $160.00 |
| June 3, 2026 | HSBC | Maintains | Buy | $150.00 |
| May 6, 2026 | JP Morgan | Maintains | Overweight | $165.00 |
| May 6, 2026 | Barclays | Maintains | Overweight | $160.00 |
| April 20, 2026 | Canaccord Genuity | Maintains | Hold | $145.00 |
| April 14, 2026 | Barclays | Maintains | Overweight | $145.00 |
| April 6, 2026 | Evercore ISI Group | Maintains | Outperform | $140.00 |
| March 23, 2026 | HC Wainwright & Co. | Maintains | Buy | $208.00 |
| February 25, 2026 | UBS | Maintains | Buy | $195.00 |
| February 25, 2026 | Barclays | Maintains | Overweight | $175.00 |
| February 25, 2026 | Wells Fargo | Maintains | Overweight | $180.00 |
| February 25, 2026 | Evercore ISI Group | Maintains | Outperform | $170.00 |
| January 16, 2026 | UBS | Maintains | Buy | $200.00 |
| December 15, 2025 | Barclays | Maintains | Overweight | $200.00 |
| December 15, 2025 | Wells Fargo | Maintains | Overweight | $190.00 |
| October 29, 2025 | Canaccord Genuity | Maintains | Hold | $165.00 |
| October 29, 2025 | Barclays | Maintains | Overweight | $175.00 |
| October 7, 2025 | Evercore ISI Group | Maintains | Outperform | $175.00 |
| October 2, 2025 | Barclays | Maintains | Overweight | $160.00 |
| September 22, 2025 | Evercore ISI Group | Upgrades | Outperform | $155.00 |
| September 12, 2025 | Jefferies | Maintains | Hold | $135.00 |
| September 3, 2025 | HC Wainwright & Co. | Reiterates | Buy | $180.00 |
Prediction markets
Live event probabilities associated with this company or market.
Bioprocessing market recovery and demand sustainability
Bull case
Repligen's strong Q1 2026 results and management's confidence in full-year demand signal a credible bioprocessing recovery. Investors are increasingly viewing RGEN as a focused play on improving biologics manufacturing spending, with new order trends and a China OEM partnership reinforcing the recovery narrative.
Bear case
Repligen's reliance on forward-looking statements regarding bioprocessing demand recovery raises investor concerns. The absence of specific performance guidance in its Q2 2026 reporting announcement introduces uncertainty about whether the recovery is durable or whether projections are overly optimistic.
Stock valuation and price target divergence
Bull case
Multiple Wall Street analysts maintain constructive ratings with a median price target of $160, and Benchmark's Robert Wasserman set an aggressive target of $185 following a Buy upgrade in July 2026. JP Morgan's Overweight rating with a $165 target further reflects confidence in Repligen's upside potential.
Bear case
Despite analyst optimism, technical indicators show RGEN trading within a wide and falling short-term trend, with both short- and long-term moving averages issuing sell signals. The stock is projected to fall approximately 10% over the next three months, suggesting the market has not embraced analyst price targets.
Portfolio focus and impact of non-core divestitures
Bull case
Management's decision to divest a non-core filtration business reflects a sharper strategic focus on profitable growth. Analysts view this portfolio streamlining as a positive signal, reinforcing confidence in Repligen's core bioprocessing competencies and its ability to generate higher-quality earnings going forward.
Bear case
Repligen's divestiture activity and corporate repositioning, while framed as strategic, could mask underlying concerns about revenue diversification. The company's concentrated exposure to bioprocessing technologies means any sector-specific slowdown would have an outsized negative impact with fewer business segments to buffer performance.